Human plasma fractionation and the impact of new technologies on the use and quality of plasma-derived products.
Recent years brought several important changes in the domain of human plasma derived products. High purity and effective anti-viral treatment became a reality. This radically improved the quality of patient treatment. At the same time recent discoveries in molecular biology paved the way for the production of several crucial plasma components by recombinant technology. In the light of these developments the future possibilities for different plasma components production is widely discussed and the eventual benefit of more expensive technologies is being evaluated. This paper, analyzes and presents methods applied by different producers to obtain plasma derived components preparations. The impact of these technologies, the quality of the products and the future of the plasma industry is being discussed.
Brodniewicz-Proba
T
T
Coagulation Factor Unit, Centre de fractionnement sanguin Armand-Frappier, Laval des Rapides, Québec, Canada.
D001709:Biotechnology; D001781:Blood Component Removal / Q000379:methods*; D005591:Chemical Fractionation; D005164:Factor IX / Q000302:isolation & purification; D005169:Factor VIII / Q000302:isolation & purification; D006801:Humans; D010949:Plasma / Q000737:chemistry*; D011786:Quality Control; D012709:Serum Albumin / Q000302:isolation & purification
D012709:Serum Albumin; D005169:Factor VIII; D005164:Factor IX